Since early 2020, the entire world has been facing a disastrous outbreak of the SARS-CoV-2 virus, with massive reporting of death and infections per day. Medical practitioners adopted …
X Wang, A Hu, X Chen, Y Zhang, F Yu, S Yue… - … and Targeted Therapy, 2022 - nature.com
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic of novel coronavirus disease (COVID-19). The neutralizing monoclonal …
JY Kim, O Săndulescu, LL Preotescu… - Open forum …, 2022 - academic.oup.com
Background We evaluated clinical effectiveness of regdanvimab (CT-P59), a severe acute respiratory syndrome coronavirus 2 neutralizing monoclonal antibody, in reducing disease …
O Săndulescu, CG Apostolescu… - Frontiers in …, 2023 - frontiersin.org
This article systematically presents the current clinically significant therapeutic developments for the treatment of COVID-19 by providing an in-depth review of molecular …
S Iketani, DD Ho - Cell Chemical Biology, 2024 - cell.com
Over four years have passed since the beginning of the COVID-19 pandemic. The scientific response has been rapid and effective, with many therapeutic monoclonal antibodies and …
CT-P59, a monoclonal antibody with potent neutralizing activity against severe acute respiratory syndrome coronavirus 2, may ameliorate symptoms and prevent hospitalization …
S Lee, SO Lee, JE Lee, KH Kim, SH Lee… - International …, 2022 - Elsevier
Abstract Background Regdanvimab (CT-P59) is a neutralizing antibody authorized in Republic of Korea for the treatment of adult patients with moderate or mild-COVID-19 who …
S Dichtl, G Diem, M Jaeger, V Zaderer, G Lupoli… - Antiviral Research, 2023 - Elsevier
The identification of the SARS-CoV-2 Omicron variants BA. 4/BA. 5, BF. 7 and BQ. 1.1 immediately raised concerns regarding the efficacy of currently used monoclonal antibody …
T Kim, DH Joo, SW Lee, J Lee, SJ Lee… - Journal of Clinical …, 2022 - mdpi.com
Background: This study aims to evaluate the real-world effectiveness of regdanvimab on clinical outcomes in patients with mild to moderate coronavirus disease 2019 (COVID-19) …